Elevated soluble intercellular adhesion molecule-1 levels in patients with systemic lupus erythematosus: Relation to insulin resistance

Journal of Rheumatology

Volumn 34, Issue 4, 2007, Pages 726-730

  Tso, Tim K ^a   Huang, Wen Nan ^b  

^a NATIONAL CHIAYI UNIVERSITY   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Insulin resistance; Soluble intracellular adhesion molecule 1; Soluble vascular cell adhesion molecule 1; Systemic lupus erythematosus

Indexed keywords

GLUCOSE; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CELL INTERACTION; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; HOMEOSTASIS; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; BIOLOGICAL MARKERS; BLOOD GLUCOSE; FEMALE; HUMANS; INSULIN RESISTANCE; INTERCELLULAR ADHESION MOLECULE-1; LUPUS ERYTHEMATOSUS, SYSTEMIC; VASCULAR CELL ADHESION MOLECULE-1;

EID: 34247356631     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Amital H, Shoenfeld Y. Autoimmunity and autoimmune diseases such as systemic lupus erythematosus. In: Lahita RG, editor. Systemic lupus erythematosus. New York: Academic Press; 1999:1-11.
2. Staunton DE, Merluzzi VJ, Rothlein R, Barton R, Martin SD, Springer TA. A cell adhesion molecule, ICAM-1, is the major surface receptor for rhinoviruses. Cell 1989;56:849-53.
3. McMurray RW. Adhesion molecules in autoimmune disease. Semin Arthritis Rheum 1996;25:215-33.
4. Mojcik CF, Shevach EM. Adhesion molecules: a rheumatologic perspective. Arthritis Rheum 1997;40:991-1004.
5. Kaplanski G, Cacoub P, Farnarier C, et al. Increased soluble vascular cell adhesion molecule-1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome. Arthritis Rheum 2000;43:55-64.
6. Horak P, Scudla V, Hermanova Z, et al. Clinical utility of selected disease activity markers in patients with systemic lupus erythematosus. Clin Rheumatol 2001;20:337-44.
7. Spronk PE, Bootsma H, Huitema MG, Limburg PC, Kallenberg CG. Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE): a long-term prospective study. Clin Exp Immunol 1994;97:439-44.
8. Wellicome SM, Kapahi P, Mason JC, Lebranchu Y, Yarwood H, Haskard DO. Detection of a circulating form of vascular cell adhesion molecule-1: raised levels in rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol 1993;92:412-8.
9. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004;25:4-7.
10. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RL. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
11. Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio Heart Study. Diabetes Care 1997;20:1087-92.
12. Tso TK, Huang HY, Chang CK, Liao YJ, Huang WN. Clinical evaluation of insulin resistance and β-cell function by the homeostasis model assessment in patients with systemic lupus erythematosus. Clin Rheumatol 2004;23:416-20.
13. Posadas-Romero C, Torres-Tamayo M, Zamora-Gonzalez J, et al. High insulin levels and increased low-density lipoprotein oxidizability in pediatric patients with systemic lupus erythematosus. Arthritis Rheum 2004;50:160-5.
14. Bruce IN. "Not only ... but also": factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology Oxford 2005;44:1492-502.
15. El-Magadmi M, Ahmad Y, Turkie W, et al. Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. J Rheumatol 2006;33:50-6.
16. Sada KE, Yamasaki Y, Maruyama M, et al. Altered levels of adipocytokines in association with insulin resistance in patients with systemic lupus erythematosus. J Rheumatol 2006;33:1545-52.
17. Straczkowski M, Lewczuk P, Dzienis-Straczkowska S, Kowalska I, Stepien A, Kinalska I. Elevated soluble intercellular adhesion molecule-1 levels in obesity: relationship to insulin resistance and tumor necrosis factor-α system activity. Metabolism 2002;51:75-8.
18. Pontiroli AE, Pizzocri P, Koprivec D, et al. Body weight and glucose metabolism have a different effect on circulating levels of ICAM-1, E-selectin, and endothelin-1 in humans. Eur J Endocrinol 2004;150:195-200.
19. Matsumoto K, Sera Y, Nakamura H, Ueki Y, Miyake S. Serum concentrations of soluble adhesion molecules are related to degree of hyperglycemia and insulin resistance in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2002;55:131-8.
20. Chen NG, Holmes M, Reaven GM. Relationship between insulin resistance, soluble adhesion molecules, and mononuclear cell binding in healthy volunteers. J Clin Metab Endocrinol 1999;84:3485-9.
21. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
22. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
23. Sari RA, Taysi S, Erdem F, et al. Correlation of serum levels of soluble intercellular adhesion molecule-1 with disease activity in systemic lupus erythematosus. Rheumatol Int 2002;21:149-52.
24. Gattorno M, Vignola S, Barbano G, et al. Tumor necrosis factor-induced adhesion molecule serum concentrations in Henoch-Schonlein purpura and pediatric systemic lupus erythematosus. J Rheumatol 2000;27:2251-5.
25. Egerer K, Feist E, Rohr U, Pruss A, Burmester GR, Dorner T. Increased serum soluble CD14, ICAM-1 and E-selectin correlate with disease activity and prognosis in systemic lupus erythematosus. Lupus 2000;9:614-21.
26. Ho CY, Wong CK, Li EK, Tarn LS, Lam CWK. Elevated plasma concentrations of nitric oxide, soluble thrombomodulin and soluble vascular cell adhesion molecule-1 in patients with systemic lupus erythematosus. Rheumatology Oxford 2003;42:117-22.
27. Janssen BA, Luqmani RA, Gordon C, et al. Correlation of blood levels of soluble vascular cell adhesion molecule-1 with disease activity in systemic lupus erythematosus and vasculitis. Br J Rheumatol 1994;33:1112-6.
28. Ikeda Y, Fujimoto T, Ameno M, Shiiki H, Dohi K. Relationship between lupus nephritis activity and the serum level of soluble VCAM-1. Lupus 1998;7:347-54.
29. Chang DM, Lan JL, Lin HY, Luo SF. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus. Arthritis Rheum 2002;46:2924-7.
30. Gomez D, Correa PA, Gomez LM, Cadena J, Molina JF, Anaya JM. Th-1/Th-2 cytokines in patients with systemic lupus erythematosus: is tumor necrosis factor a protective? Semin Arthritis Rheum 2004;33:404-13.
31. Grossman JM, Kalunian KC. Definition, classification, activity, and damage indices. In: Wallace DJ, Hahn BH, editors. Dubois' lupus erythematosus. Philadelphia: Lippincott, Williams and Wilkins; 2002:19-31.
32. van de Stolpe A, van der Saag PT. Intercellular adhesion molecule-1. J Mol Med 1996;74:13-33.
33. Marfella R, Esposito K, Giunta R, et al. Circulating adhesion molecules in humans: role of hyperglycemia and hyperinsulinemia. Circulation 2000;101:2247-51.
34. Kent JW Jr, Comuzzie AG, Mahaney MC, et al. Intercellular adhesion molecule-1 concentration is genetically correlated with insulin resistance, obesity, and HDL concentration in Mexican Americans. Diabetes 2004;53:2691-5.
35. Hak AE, Pols HA, Stehouwer CD, et al. Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly: the Rotterdam study. J Clin Endocrinol Metab 2001;86:4398-405.
36. Anjos-Valotta EA, Martins JO, Oliveira MA, et al. Inhibition of tumor necrosis facto-alpha-induced intercellular adhesion molecule-1 expression in diabetic rats: role of insulin. Inflamm Res 2006;55:16-22.